GSK-backed Lyell Immunopharma, fresh off a near $500M cash injection, guns for a $150M IPO

Retrieved on: 2021-05-26 11:15:00

Tags for this article:

Click the tags to see associated articles and topics

GSK-backed Lyell Immunopharma, fresh off a near $500M cash injection, guns for a $150M IPO. View article details on hiswai:

Excerpt

“We are applying our Gen-R and Epi-R technology platforms to our lead CAR program, LYL797, which is expected to be an intravenous (IV) ...

Article found on: www.fiercebiotech.com